Trial · NCT03776175
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 | Placebo | 8.14 | 90% Confidence Interval -8.56 to 27.89 | percent change | |
| Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 | PF-05221304 15mg + Placebo | -40.01 | 90% Confidence Interval -47.00 to -32.09 | percent change | |
| Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 | PF-06865571 300 mg + Placebo | -30.14 | 90% Confidence Interval -37.97 to -21.33 | percent change | |
| Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 | PF-05221304 15 mg + PF-06865571 300 mg | -40.13 | 90% Confidence Interval -46.58 to -32.90 | percent change | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | Participants With AEs | 3 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | PF-05221304 15mg + Placebo | Participants With AEs | 10 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | PF-06865571 300 mg + Placebo | Participants With AEs | 10 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | PF-05221304 15 mg + PF-06865571 300 mg | Participants With AEs | 10 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | Participants With SAEs | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | PF-05221304 15mg + Placebo | Participants With SAEs | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | PF-06865571 300 mg + Placebo | Participants With SAEs | 0 | Participants | |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | PF-05221304 15 mg + PF-06865571 300 mg | Participants With SAEs | 1 | Participants | |
| Number of Participants With Laboratory Abnormalities | Placebo | 6 | Participants | ||
| Number of Participants With Laboratory Abnormalities | PF-05221304 15mg + Placebo | 17 | Participants | ||
| Number of Participants With Laboratory Abnormalities | PF-06865571 300 mg + Placebo | 11 | Participants | ||
| Number of Participants With Laboratory Abnormalities | PF-05221304 15 mg + PF-06865571 300 mg | 6 | Participants | ||
| Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Blood Pressure | Placebo | Maximum increase: Systolic blood pressure | 10.8 | Standard Deviation 6.59 | millimeter of mercury |
| Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Blood Pressure | PF-05221304 15mg + Placebo | Maximum increase: Systolic blood pressure | 7.0 | Standard Deviation 7.77 | millimeter of mercury |
| Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Blood Pressure | PF-06865571 300 mg + Placebo | Maximum increase: Systolic blood pressure | 9.6 | Standard Deviation 11.38 | millimeter of mercury |
| Maximum Change (Increase or Decrease) From Baseline to Post-last Dose of Study Drug in Vital Signs: Blood Pressure | PF-05221304 15 mg + PF-06865571 300 mg | Maximum increase: Systolic blood pressure | 7.5 | Standard Deviation 12.58 | millimeter of mercury |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03776175/results